Igea Med
On 18 December 2020, Igea Med S.p.A. obtained admission to negotiate ordinary shares on AIM Italia, a multilateral negotiations system organized and managed by Borsa Italiana. Negotiations began on 22 December 2020.
Integrae SIM acted as Nomad and Global Coordinator.
The equivalent of the placement of a total of 259,000 shares and at the start date of the negotiations on AIM Italia PRO, the share capital of Igeamed S.p.A. will be represented by a total of 2,259,000 ordinary shares with a float of 11.47% for a planned capitalization equal to € 3,388,500.
The enterprise. Igeamed, a company of the Igeam Group, operates in the market of medicine for companies and provides companies with integrated consulting and engineering services for risk management and human resources. Igeamed, which operates entirely in Italy through a capillary structure with four operational headquarters throughout the country and, in particular, in Bari, Rome, Ravenna, and Milan, aims to promote corporate healthcare, representing the ideal partner to address the new needs of companies increasingly oriented towards social responsibility and the overall well-being of employees and the company system as a whole.
Ultima Ricerca Igea Med
UPDATE| Borgosesia reported results in line with the Business Plan, confirming a stable operating model and high profitability. Consolidated revenues amounted to €14.43 million, supported by real estate sales and income from repossession strategy receivables. Gross operating profit stood at €9.61 million, undergoing physiological normalization but still accounting for more than 50.0% of revenues, while EBITDA amounted to €7.29 million (margin of 52.5%) with net income of €2.08 million. On the strategic front, tangible progress has been made: the growth in AUM to €133.00 million (compared to €79.00 million at December 31, 2024) confirms the progress of the third-party management model, despite a natural phase of building fundraising capacity in a highly competitive market. Finally, disposals and collections during the period contributed to the improvement in Adj. NFP to €85.02 million, freeing up resources and strengthening the financial structure. Overall, the half-year shows concrete progress in the transformation process and lays a solid foundation for the expansion of recurring and asset-light activities. Considering the performance in the first half of the year and the Company’s recent announcements, we see no reason to update the forecasts made in the previous report. We expect FY25E production value to be €25.50 million with EBITDA of €12.50 million, corresponding to a margin of 49.0%, and growth in production value to €32.7 million (CAGR 24A-27E: 10.1%) in FY27E, with EBITDA of €19.00 million and a margin of 58.1%. We confirm our target price of €2.50, BUY rating, and MEDIUM risk. |
